Regeneron Reports First Quarter 2023 Financial and Operating Results
May 04, 2023 06:30 ET
|
Regeneron Pharmaceuticals, Inc.
First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first...
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
May 02, 2023 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
Oral presentations include interim results from pivotal trial of linvoseltamab (BCMAxCD3) in relapsed/refractory multiple myeloma and three cohorts of fianlimab (LAG-3 inhibitor) combined with...
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023 16:05 ET
|
Regeneron Pharmaceuticals, Inc.
- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging Clinical...
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
April 17, 2023 07:30 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company’s...
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
April 17, 2023 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
New subgroup data and further analyses of the aflibercept 8 mg clinical trial program to highlight durability results of extended dosing intervals, patient characteristics, and efficacy and safety in...
Regeneron Announces Investor Conference Presentations
April 11, 2023 16:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., April 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2023 Health Care Conference at...
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
April 03, 2023 16:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2023 financial and operating results on...
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
March 29, 2023 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday...
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
March 28, 2023 07:30 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration...
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
March 23, 2023 02:00 ET
|
Regeneron Pharmaceuticals, Inc.
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo First and only biologic to show rapid and significant...